Participate in the Cancer & Evolution Monthly Webcasts
We are very pleased to announce that our Cancer&Evolution.org group has decided to continue the successful, landmark Cancer & Evolution Symposium, held on October 14-16, 2020, as a monthly virtual Cancer & Evolution Seminar Series (CESS).
The format for each Cancer & Evolution seminar will be a 90-minute (Zoom) program, guided by a moderator, with two speakers presenting for 25 minutes with 5 minutes of Q&A for each, followed by a 30-minute scientific group discussion.
CESS kicked off on Thursday, December 3rd, 2020, and our seminars will typically be held from 11 am to 12:30 pm Eastern Time (ET) on the first Thursday of every month.
As part of our CESS out-reach program, many of our seminars will be co-hosted, e.g. by a department, institute or center, and scientists and cancer researchers at the co-hosting institution will be invited to the respective seminar. Registration is not required, and the seminars are free of charge.
We hope you will be able to participate actively and frequently in the fascinating CESS scientific and cancer research presentations and discussions. We are always looking for feedback, suggestions, recommendations for speakers, referrals, and we anticipate that, just like the symposium, our new Cancer & Evolution seminar series will be very interactive.
With best wishes,
The Cancer&Evolution.org group
Every month, two leading researchers present their latest findings about cancer as an evolutionary phenomenon. Sign up to receive notifications and links to each session.
Speaker Schedule (full details follow below)
|Dec 3, 2020||Frank Laukien||Jonathan Losos, Washington University|
Casimir Bamberger, Scripps Res. Institute
|Harvard Origins of Life Initiative & Wyss Institute at Harvard|
|Jan 7, 2021||Azra Raza||Carlos Sonnenschein, Tufts University|
Joshua Ofman, Grail, Inc.
|Columbia MDS Center|
|Feb 4, 2021||Jeff Townsend||Jason Somarelli, Duke University||Yale School of Public Health|
|March 4 or 11, 2021||Ann Barker||tbd||Ellison Institute for Transformative Medicine, USC|
|April 1, 2021||Kenneth Pienta||Robert Austin, Princeton University|
Joel Brown, Moffit Cancer Center
|Johns Hopkins School of Medicine|
|May 6, 2021||Denis Noble||Sui Huang, Institute for Systems Biology|
Jean-Jacques Kupiec, ENS (Paris), France
|Physiology, Anatomy & Genetics Dpmt, U. of Oxford|
|June 3, 2021||Charles Swanton||tbd||Francis Crick Institute|
January 7, 2021
Azra Raza, M.D.
Professor of Medicine, Director - MDS Center, Columbia University Medical Center; Author, The First Cell: And the Human Costs of Pursuing Cancer to the Last
Carlos Sonnenschein, MD
Professor, Tufts University School of Medicine
Integrative Physiology & Pathobiology
Title: Deciding on Cancer Theories
Abstract: My presentation will briefly discuss the premises that have been adopted to propose the somatic mutation theory (SMT) and its multiple variants and the tissue organization field theory (TOFT) of carcinogenesis. In addition, I will discuss the merits of both theories and the answers they have provided to important questions in cancer research, in clinical cancer and to biology at large.
Joshua J. Ofman, MD, MSHS
Chief Medical Officer and External Affairs
Title: Novel Approaches to Multi-Cancer Early Detection
Abstract: Dr. Ofman will discuss the landscape of current cancer screening, and the potential for MCED technology to impact public health.
December 3, 2020
Frank H. Laukien, Ph.D.
Co-Organizer of Cancer & Evolution Symposium; Author, Natural Evolution 4.0: Feedback-Driven and Actively Accelerated Biological Evolution; Chairman, President & CEO, Bruker Corporation
Jonathan Losos, Ph.D.
Director, Living Earth Collaborative; William H. Danforth Distinguished University Professor; Department of Biology, Washington University in St. Louis; Author, Improbable Destinies: Fate, Chance, and the Future of Evolution (2017)
Title: Fate and Chance in Evolution: A Lizard's Tale
Abstract: Are the plants and animals that exist today, and we humans ourselves, predictable inevitabilities or historical flukes, the happy, but improbable, result of the particular chain of events that occurred over Earth’s history? And what might these debates suggest about life on other planets? Stephen Jay Gould famously posed this question with his “replay the tape” metaphor 30 years ago. Inspired by Gould, biologists have developed two research programs to test the question of evolutionary repeatability. Some have pointed to the pervasiveness of convergent evolution as evidence that evolution commonly finds the same adaptive solutions, while others have replayed the tape by conducting replicated experiments in the laboratory and, increasingly, in the field to directly test Gould’ postulate. As is often the case, the results are mixed: evolution is sometimes highly repeatable, in other cases critically contingent on circumstances. The challenge now is to understand not whether evolution is repeatable, but why it is sometimes and not others.
Casimir Bamberger, Ph.D.
Research Scientist, The Scripps Research Institute, Group of Professor John Yates; Previously a cell biology post-doc at ETH Zurich, and later at Harvard Medical School; PhD in biology from the University of Hamburg
Title: A Survey of the Cancer Conformational Landscape and its Evolution with 3D Proteomics
The current paradigm in cancer research states that somatic mutations drive malignant transformation by altering the abundance, structure or interactions of proteins. However, the full extent of altered protein conformations and interactions in the cancer proteome is only partially known. To address this gap in knowledge we developed Covalent Protein Painting (CPP), which is a novel mass spectrometric method that allows us to sample aberrant protein conformations in the 3D proteome of cancer cells with exquisite sensitivity. Using CPP, we surveyed the 3D proteome of 60 different cancer cell lines (NCI60) that harbor a total of 461 somatically mutated genes.
Here, I will explore the consequences of a single point mutation upon the 3D proteome and describe commonalities in aberrant protein conformations across all 60 NCI cancer cell lines. Based on the findings I conclude that the sequence of somatic mutation events is more important than the contribution of each somatic mutation alone to the conformational landscape of the cancer proteome, and thus for the evolution and maintenance of malignancy. With this insight we performed an in silico screen and find 49 conformational changes in non-mutated proteins that predict the efficacy of 300 small molecules to kill tumor cells. In conclusion, these 49 protein sites might be conformational biomarkers to determine anti-cancer drug efficacy or might be direct targets for anticancer drug development.
Frank H. Laukien
James A. Shapiro
Henry H. Heng
Symposium Planning & Execution Team
Tamra V. Thorne
M. William Audeh
Anna D. Barker
Steven A. Carr
Kenneth J. Pienta